Optimization of Antisense Oligonucleotide Drugs for Skipping Dystrophin Exon 51 and 53 in Duchenne Muscular Dystrophy

被引：0
|
作者：
Wu, Bo [1 ]
机构：
[1] Carolinas Med Ctr, Charlotte, NC 28203 USA
来源：
MOLECULAR THERAPY | 2018年 / 26卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
315
引用
收藏
页码：148 / 148
页数：1
相关论文
共 50 条
  • [31] Antisense-induced exon skipping in Duchenne muscular dystrophy patients
    Janson, A. A. M.
    Ginjaar, I. H. B.
    Aartsma-Rus, A.
    van Ommen, G. -J. B.
    van der Kooi, A.
    de Kimpe, S.
    Ekhart, P.
    Platenburg, G.
    Verschumen, J. J. G. M.
    van Deutekom, J. C. T.
    NEUROMUSCULAR DISORDERS, 2006, 16 (9-10) : 722 - 722
  • [32] Exon skipping in Duchenne muscular dystrophy
    Wilton, Steve
    NEUROMUSCULAR DISORDERS, 2008, 18 (05) : 431 - 432
  • [33] Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
    Komaki, Hirofumi
    Nagata, Tetsuya
    Saito, Takashi
    Masuda, Satoru
    Takeshita, Eri
    Sasaki, Masayuki
    Tachimori, Hisateru
    Nakamura, Harumasa
    Aoki, Yoshitsugu
    Takeda, Shin'ichi
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (437)
  • [34] Accurate quantification of dystrophin mRNA and exon skipping levels in Duchenne Muscular Dystrophy
    Spitali, Pietro
    Heemskerk, Hans
    Vossen, Rolf H. A. M.
    Ferlini, Alessandra
    den Dunnen, Johan T.
    't Hoen, Peter A. C.
    Aartsma-Rus, Annemieke
    LABORATORY INVESTIGATION, 2010, 90 (09) : 1396 - 1402
  • [35] Dual exon skipping in myostatin and dystrophin as a potential therapy for Duchenne muscular dystrophy
    Kemaladewi, D. U.
    Hoogaars, W. M. H.
    van Heiningen, S. H.
    van Deutekom, J. C. T.
    den Dunnen, J. T.
    van Ommen, G. J. B.
    Aartsma-Rus, A. R.
    ten Dijke, P.
    't Hoen, P. A. C.
    NEUROMUSCULAR DISORDERS, 2009, 19 (8-9) : 577 - 577
  • [36] The influence of antisense oligonucleotide length on dystrophin exon skipping
    Harding, P. L.
    Fall, A. M.
    Honeyman, K.
    Fletcher, S.
    Wilton, S. D.
    MOLECULAR THERAPY, 2007, 15 (01) : 157 - 166
  • [37] Development of Antisense-Mediated Exon Skipping as a Treatment for Duchenne Muscular Dystrophy
    Heemskerk, Hans
    de Winter, Christa L.
    van Ommen, Gert-Jan B.
    van Deutekom, Judith C. T.
    Aartsma-Rus, Annemieke
    OLIGONUCLEOTIDE THERAPEUTICS, 2009, 1175 : 71 - 79
  • [38] Targeting a Novel Site in Exon 51 with Antisense Oligonucleotides Induces Enhanced Exon Skipping in a Mouse Model of Duchenne Muscular Dystrophy
    Oppeneer, Todd
    Qi, Yulan
    Henshaw, Joshua
    Larimore, Kevin
    Melton, Andrew
    Puolivali, Jukka
    Carter, Caitlyn
    Fant, Pierluigi
    Brennan, Sebastian
    Wetzel, Laura A.
    Sigg, Monika A.
    Crawford, Brett E.
    Magat, Jenna
    Froelich, Steven
    Woloszynek, Josh C.
    O'Neill, Charles A.
    NUCLEIC ACID THERAPEUTICS, 2025,
  • [39] An opening in Duchenne muscular dystrophy:: persistent therapeutic rescue of dystrophin by vectorized antisense mediated exon skipping in mdx mice
    Goyenvalle, A
    Vulin, A
    Fougerousse, F
    Leturcq, F
    Kaplan, JC
    Garcia, L
    Danos, O
    M S-MEDECINE SCIENCES, 2004, 20 (12): : 1163 - 1165
  • [40] Optimization of preclinical antisense oligonucleotide development for Duchenne muscular dystrophy
    Kolfschoten, I. G. M.
    Janson, A. A. M.
    van den Eijnde, R. E. Y.
    Bijl, S.
    Zonneveld-Mulder, M. H. C.
    de Visser, P. C.
    van Deutekom, J. C. T.
    NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 803 - 804
12345